06 agosto 2020
Goldman Sachs says investors are underestimating the chance of a COVID-19 vaccine in 2020
Goldman Sachs says investors are underestimating the chance of a COVID-19 vaccine in 2020, an event that could push the S&P 500 11% higher: "We agree that there is now a good chance that at least one vaccine will be FDA-approved by the end of November and broadly distributed by the middle of 2021," they added.
-
The Value of a Cure: An Asset Pricing Perspective : We provide an estimate of the value of a cure using the joint behavior of stock prices ...
-
COVID - 19 Guidance for Hospital Reporting and FAQs For Hospitals, Hospital Laboratory, and Acute Care Facility Data Reporting : It is crit...
-
Coronavirus Could Push More Than 1 Billion People to Extreme Poverty : Due to the severe long-term impact of the months-long coronavirus p...